[A16-30] Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V
Last updated 30.09.2016
Commission awarded on 13.05.2016 by the Federal Joint Committee (G-BA).
Immune system and infections
The current version 1.1 of the dossier assessment replaces version 1.0 published on 15 August 2016.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.